1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006; 16:109–142. PMID:
16420177.
2. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper DS, Doherty , GM , Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19:1167–1214. PMID:
19860577.
3. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26:1–133. PMID:
26462967.
4. Haddad RI, Bischoff L, Busaidy NL, Dickson P, Duh QY, Ehya H, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for thyroid carcinoma, version 2.2019. Fort Washington, PA: National Comprehensive Cancer Network, Inc.;2019.
5. Amit M, Tam S, Boonsripitayanon M, Cabanillas ME, Busaidy NL, Grubbs EG, et al. Association of lymph node density with survival of patients with papillary thyroid cancer. JAMA Otolaryngol Head Neck Surg. 2018; 144:108–114. PMID:
29192312.
6. Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012; 22:1144–1152. PMID:
23083442.
7. Dobrinja C, Troian M, Cipolat Mis T, Rebez G, Bernardi S, Fabris B, et al. Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: is there anything more to say? A decade experience in a single-center. Int J Surg. 2017; 41 Suppl 1:S40–S47. PMID:
28506412.
8. Ywata de Carvalho A, Chulam TC, Kowalski LP. Long-term results of observation vs prophylactic selective level VI neck dissection for papillary thyroid carcinoma at a cancer center. JAMA Otolaryngol Head Neck Surg. 2015; 141:599–606. PMID:
25997016.
9. Zhao W, You L, Hou X, Chen S, Ren X, Chen G, et al. The effect of prophylactic central neck dissection on locoregional recurrence in papillary thyroid cancer after total thyroidectomy: a systematic review and meta-analysis: pCND for the locoregional recurrence of papillary thyroid cancer. Ann Surg Oncol. 2017; 24:2189–2198. PMID:
27913945.
10. Wang TS, Cheung K, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. Ann Surg Oncol. 2013; 20:3477–3483. PMID:
23846784.
11. Ryu YJ, Cho JS, Park MH, Yoon JH. Identifying risk factors of recurrence for clinically node negative papillary thyroid carcinoma with pathologic N1a. BMC Surg. 2019; 19:78. PMID:
31277631.
12. Song E, Han M, Oh HS, Kim WW, Jeon MJ, Lee YM, et al. Lobectomy is feasible for 1-4 cm papillary thyroid carcinomas: a 10-year propensity score matched-pair analysis on recurrence. Thyroid. 2019; 29:64–70. PMID:
30375260.
13. Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol. 2015; 33:2370–2375. PMID:
26077238.
14. Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg. 2005; 71:731–734. PMID:
16468507.
15. Choudhury PS, Gupta M. Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol. 2018; 91:20180136. PMID:
30260232.
16. Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffé S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab. 2012; 97:1526–1535. PMID:
22344193.
17. Lamartina L, Durante C, Filetti S, Cooper DS. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J Clin Endocrinol Metab. 2015; 100:1748–1761. PMID:
25679996.
18. Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003; 237:399–407. PMID:
12616125.
19. Cranshaw IM, Carnaille B. Micrometastases in thyroid cancer. An important finding? Surg Oncol. 2008; 17:253–258. PMID:
18504121.
20. Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol. 2005; 12:81–89. PMID:
15827782.
21. Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010; 136:1055–1061. PMID:
21079156.
22. Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck. 2011; 33:645–649. PMID:
20687168.
23. Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014; 260:601–605. PMID:
25203876.
24. Rajjoub SR, Yan H, Calcatera NA, Kuchta K, Wang CE, Lutfi W, et al. Thyroid lobectomy is not sufficient for T2 papillary thyroid cancers. Surgery. 2018; 163:1134–1143. PMID:
29426618.
25. Hauch A, Al-Qurayshi Z, Randolph G, Kandil E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol. 2014; 21:3844–3852. PMID:
24943236.
26. Liang J, Li Z, Fang F, Yu T, Li S. Is prophylactic central neck dissection necessary for cN0 differentiated thyroid cancer patients at initial treatment? A meta-analysis of the literature. Acta Otorhinolaryngol Ital. 2017; 37:1–8. PMID:
28374865.
27. Ahn JE, Lee JH, Yi JS, Shong YK, Hong SJ, Lee DH, et al. Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. World J Surg. 2008; 32:1552–1558. PMID:
18408961.
28. Lang BH, Wong KP, Wan KY, Lo CY. Impact of routine unilateral central neck dissection on preablative and postablative stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma. Ann Surg Oncol. 2012; 19:60–67. PMID:
21681379.
29. Raffaelli M, Tempera SE, Sessa L, Lombardi CP, De Crea C, Bellantone R. Total thyroidectomy versus thyroid lobectomy in the treatment of papillary carcinoma. Gland Surg. 2020; 9(Suppl 1):S18–S27. PMID:
32055495.
30. Park JH, Yoon JH. Lobectomy in patients with differentiated thyroid cancer: indications and follow-up. Endocr Relat Cancer. 2019; 26:R381–R393. PMID:
31018176.